AQR Capital Management LLC Has $6.31 Million Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

AQR Capital Management LLC increased its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 6.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 839,274 shares of the biotechnology company's stock after acquiring an additional 52,047 shares during the quarter. AQR Capital Management LLC owned about 0.41% of BioCryst Pharmaceuticals worth $6,311,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of BCRX. Vanguard Group Inc. raised its holdings in BioCryst Pharmaceuticals by 7.8% in the 4th quarter. Vanguard Group Inc. now owns 21,890,422 shares of the biotechnology company's stock worth $164,616,000 after acquiring an additional 1,583,826 shares during the period. Eversept Partners LP raised its holdings in BioCryst Pharmaceuticals by 269.9% in the 4th quarter. Eversept Partners LP now owns 1,980,312 shares of the biotechnology company's stock worth $14,892,000 after acquiring an additional 1,444,907 shares during the period. Hillsdale Investment Management Inc. raised its holdings in BioCryst Pharmaceuticals by 65,213.3% in the 4th quarter. Hillsdale Investment Management Inc. now owns 542,100 shares of the biotechnology company's stock worth $4,077,000 after acquiring an additional 541,270 shares during the period. Norges Bank bought a new position in BioCryst Pharmaceuticals in the 4th quarter worth $3,947,000. Finally, Schroder Investment Management Group raised its holdings in BioCryst Pharmaceuticals by 523.9% in the 4th quarter. Schroder Investment Management Group now owns 522,657 shares of the biotechnology company's stock worth $3,936,000 after acquiring an additional 438,887 shares during the period. Institutional investors own 85.88% of the company's stock.

Analysts Set New Price Targets

BCRX has been the topic of several research analyst reports. StockNews.com upgraded shares of BioCryst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Tuesday, May 6th. Royal Bank of Canada restated an "outperform" rating and issued a $13.00 price target (up from $11.00) on shares of BioCryst Pharmaceuticals in a research report on Tuesday, May 6th. Barclays raised their price target on shares of BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the stock an "equal weight" rating in a research report on Wednesday, May 7th. Evercore ISI raised their price target on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an "outperform" rating in a research report on Monday, January 13th. Finally, Needham & Company LLC raised their price target on shares of BioCryst Pharmaceuticals from $15.00 to $17.00 and gave the stock a "buy" rating in a research report on Tuesday, May 6th. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $16.56.

BioCryst Pharmaceuticals Price Performance

Shares of BioCryst Pharmaceuticals stock traded down $0.21 during trading on Tuesday, hitting $10.13. 1,259,299 shares of the company's stock traded hands, compared to its average volume of 2,993,347. The firm's fifty day moving average price is $7.92 and its 200 day moving average price is $7.90. BioCryst Pharmaceuticals, Inc. has a twelve month low of $5.34 and a twelve month high of $11.11. The company has a market cap of $2.12 billion, a PE ratio of -16.61 and a beta of 1.08.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last issued its earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The firm had revenue of $131.50 million for the quarter, compared to analyst estimates of $126.64 million. During the same quarter in the prior year, the business posted $0.28 EPS. The business's quarterly revenue was up 40.8% compared to the same quarter last year. As a group, equities research analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current year.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.